Drugs / LGT(TP21)/DEN4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00118924 | Jul 2005 → Jul 2007 | tick-borne encephalitis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LGT(TP21)/DEN4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00118924 ↗ |
| Modality | Vaccine | “Live attenuated LGT(TP21)/DEN4 vaccine (one of two doses)” NCT00118924 ↗ |
| Route | Subcutaneous | “One subcutaneous vaccination with a 10\^3 PFU dose of LGT(TP21)/DEN4 vaccine given in the deltoid region of either arm.” NCT00118924 ↗ |